- Home
- IDYA vs IBRX Comparison
IDYA vs IBRX Comparison
Compare IDYA & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- IBRX
- Stock Information
- Founded
- IDYA 2015
- IBRX 2014
- Country
- IDYA United States
- IBRX United States
- Employees
- IDYA N/A
- IBRX N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IDYA Health Care
- IBRX Health Care
- Exchange
- IDYA Nasdaq
- IBRX Nasdaq
- Market Cap
- IDYA 2.2B
- IBRX 2.3B
- IPO Year
- IDYA 2019
- IBRX N/A
- Fundamental
- Price
- IDYA $24.27
- IBRX $2.74
- Analyst Decision
- IDYA Strong Buy
- IBRX Strong Buy
- Analyst Count
- IDYA 13
- IBRX 5
- Target Price
- IDYA $51.36
- IBRX $11.40
- AVG Volume (30 Days)
- IDYA 1.1M
- IBRX 8.8M
- Earning Date
- IDYA 08-05-2025
- IBRX 08-05-2025
- Dividend Yield
- IDYA N/A
- IBRX N/A
- EPS Growth
- IDYA N/A
- IBRX N/A
- EPS
- IDYA N/A
- IBRX N/A
- Revenue
- IDYA $7,000,000.00
- IBRX $56,600,000.00
- Revenue This Year
- IDYA $101.44
- IBRX $567.98
- Revenue Next Year
- IDYA $263.37
- IBRX $160.56
- P/E Ratio
- IDYA N/A
- IBRX N/A
- Revenue Growth
- IDYA N/A
- IBRX 4227.22
- 52 Week Low
- IDYA $13.45
- IBRX $1.83
- 52 Week High
- IDYA $40.74
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- IDYA 52.57
- IBRX 52.38
- Support Level
- IDYA $22.09
- IBRX $2.45
- Resistance Level
- IDYA $24.75
- IBRX $2.94
- Average True Range (ATR)
- IDYA 1.25
- IBRX 0.14
- MACD
- IDYA -0.13
- IBRX 0.03
- Stochastic Oscillator
- IDYA 40.05
- IBRX 56.56
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.